| Literature DB >> 29483971 |
Nicola Zerbinati1, Torello Lotti2, Damiano Monticelli3, Raffaele Rauso4, Pablo González-Isaza5, Edoardo D'Este6, Alberto Calligaro7, Sabrina Sommatis8, Cristina Maccario8, Roberto Mocchi8, Jacopo Lotti9, Uwe Wollina10, Georgi Tchernev11,12, Katlein França13.
Abstract
OBJECTIVE: Neauvia Stimulate is biocompatible, injectable hyaluronic acid (HA) filler (26 mg/ml) PEG cross-linked with 1% of calcium hydroxyapatite (CaHA) for facial soft-tissue augmentation that provides volume to tissues, followed by process of neocollagenesis for improving skin quality. AIM: The aim of the present study is to evaluate the biosafety of the product (Lot. 160517-26-1/2 PEG) on human keratinocytes cultured in vitro.Entities:
Keywords: Neauvia Stimulate; biosafety; calcium hydroxyapatite; human keratinocytes; hyaluronic acid
Year: 2018 PMID: 29483971 PMCID: PMC5816290 DOI: 10.3889/oamjms.2018.044
Source DB: PubMed Journal: Open Access Maced J Med Sci ISSN: 1857-9655
Figure 1MTT reduction in formazan. The reaction is catalysed by succinate dehydrogenase
Figure 2Graphics of cell viability obtained after 24 h treatment of HaCaT cells with the product Neauvia Stimulate®. (A): MTT test; (B) NRU test; (C) Kenacid Blue assay
Figure 3Images obtained using a fluorescence microscope of the staining with LIVE/DEAD kit after 24 h treatment with the product Neauvia Stimulate®. A) Ctrl (untreated cells); B) SLS (Ctrl+); C) product 2.5 mg/ml; D) product 1.25 mg/ml
Figure 4Optical microscopy images related to EE staining after 24 h treatment of HaCaT cells with the product Neauvia Stimulate®. A) control (untreated cells); B) SLS (Ctrl +); C) product 2.5 mg/ml; D) product 1.25 mg/ml
Figure 5Images obtained using a confocal microscope of the staining with Phalloidin after 24 h treatment with the product Neauvia Stimulate®. A) Ctrl (untreated cells); B) SLS 0.1 mg/ml (Ctrl+); C) product 2.5 mg/ml; D) product 1.25 mg/ml